Working… Menu

Study of the Effects of High-dose N-acetylcysteine (NAC) in Idiopathic Pulmonary Fibrosis (IPF) (IFIGENIA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00639496
Recruitment Status : Completed
First Posted : March 20, 2008
Last Update Posted : March 5, 2015
Information provided by (Responsible Party):
Zambon SpA

Brief Summary:
The purpose of this study is to determine whether NAC added to prednisone, and azathioprine has a better effect on lung function, radiology and clinical condition than placebo + prednisone in combination with azathioprine after 6 and 12 months.

Condition or disease Intervention/treatment Phase
Pulmonary Fibrosis Drug: n-acetylcysteine Drug: placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 184 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Idiopathic Pulmonary Fibrosis International Group Exploring NAC I Annual Study of the Effects of High-dose N-acetylcysteine (NAC) in Idiopathic Pulmonary Fibrosis (IPF)
Study Start Date : March 2000
Actual Primary Completion Date : July 2003
Actual Study Completion Date : July 2003

Arm Intervention/treatment
Experimental: 1
patients taking NAC 600 mg t.i.d.
Drug: n-acetylcysteine
600 mg x 3, for 12 months
Other Name: Flumucil

Placebo Comparator: 2 Drug: placebo

Primary Outcome Measures :
  1. Vital capacity (VC) and diffusion capacity for CO (DLCO) [ Time Frame: at 6 and 12 months ]

Secondary Outcome Measures :
  1. clinical, radiologic and physiologic (CRP)-score [ Time Frame: at 6 and 12 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of IPF according to the International Consensus Statement
  • Bronchoalveolar lavage (BAL) showing no features to support an alternative diagnosis.
  • Patients in whom it was possible to determine single breath DLco.
  • Patients with newly or previously diagnosed IPF, in whom it was clinically justified to use the standardised regimen azathioprine plus prednisone

Exclusion Criteria:

  • Known intolerance to N-Acetylcysteine.
  • Patients with respiratory infections at study entry should be excluded until the infections have been treated successfully (VC and Dlco comparable with the values before the infection).
  • Patients with pre-existing disease that interferes with the evaluation of IPF: extensive old TBC lesions, significant bronchiectasis, moderate or severe COPD.
  • Patients with malignancy in the last 5 years. If the patient had a malignancy in the past and is free of malignancy for more than five years, the patient is regarded as healed.
  • Patients with heart failure.
  • Patients with hepatic function abnormalities contraindicating the use of azathioprine (i.e. clinically significant abnormalities of PTT and/or GGT).
  • Patients with a renal clearance < 10ml/min and/or hematuria and/or proteinuria of collagen vascular disease origin. A renal clearance is only performed in the presence of an abnormal serum creatinine and/or serum urea level.
  • Patients who are artificially ventilated.
  • Prednisone at a dose > 0.5 mg/kg/day (or other glucocorticoids such as triamcinolone, dexamethasone or methylprednisolone at an equivalent dose) or azathioprine at a dose > 2 mg/kg/day during the last month prior to inclusion.
  • Use of other immunosuppressives (such as cyclophosphamide and colchicine) is not allowed in the last month and for the duration of the trial.
  • Any form of anticancer therapy or methotrexate are not allowed when used for more than 1 week in the past and for the duration of the trial.
  • Amiodarone or nitrofurantoin are not allowed in the last 5 years, when used for more than 1 week in the past and for the duration of the trial.
  • Allopurinol, oxypurinol, thiopurinol, anti-oxidants (e.g. vitamin E) or glutathione supplements are not allowed in the last month and during the trial.
  • The use of interferon or other antifibrotics (e.g. pirfenidone) is not allowed in the past and during the study.
  • The use of NAC therapy at a dosage of more than 600 mg/day is not allowed in the last 3 years for a total period of more than 3 months.
  • Patients suffering or having suffered from documented active ulcer within the last 3 years.
  • Patients in whom the standardised treatment regimen is contraindicated or not justified.
  • Pregnancy.
  • Known or suspected drug or alcohol abuse.
  • Patients on other investigational compounds or participating in clinical trials on investigational compounds within the last 3 months.
  • Patients expected to be non-compliant in taking the medication.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00639496

Layout table for location information
U.Z. Ghent
Gent, Belgium, B- 9000
Hôpital A. Calmette
Lille Cedex, France, F 59037
Klinikum Grosshadern
Munich, Germany, 81377
U.O. di Pneumologia-Ospedale
Arezzo, Italy, 52100
Stichting St. Antonius Ziekenhuis
Nieuwegein, Netherlands, 3435 CM
Hospital Universitario Virgen del Rocío
Sevilla, Spain, 41013
United Kingdom
The University of Edinburgh-Medical School
Edinburgh, United Kingdom, EH8 9AG
Sponsors and Collaborators
Zambon SpA
Layout table for investigator information
Study Chair: M. Demedts, MD U.Z.-Gasthuisberg, Leuven, Belgium
Publications of Results:
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Zambon SpA Identifier: NCT00639496    
Other Study ID Numbers: 7112LAMC01
First Posted: March 20, 2008    Key Record Dates
Last Update Posted: March 5, 2015
Last Verified: March 2008
Keywords provided by Zambon SpA:
Idiopathic Pulmonary Fibrosis
Additional relevant MeSH terms:
Layout table for MeSH terms
Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Pathologic Processes
Lung Diseases
Respiratory Tract Diseases
Idiopathic Interstitial Pneumonias
Lung Diseases, Interstitial
Antiviral Agents
Anti-Infective Agents
Respiratory System Agents
Free Radical Scavengers
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs